ArticleF1000Research2020
Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives.Frontiers in pharmacology · 2026Review
- Prevalence of advanced fibrosis risk using FIB-4 in patients with type 2 diabetes and its associated factors: a cross-sectional study in a primary care unit of a university hospital in Southern Thailand.BMC primary care · 2025Article
- Evaluation of the Potential Benefits of Trimetazidine in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Label-free multimodal optical biopsy reveals biomolecular and morphological features of diabetic kidney tissue in 2D and 3D.Nature communications · 2025Article
- Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C.Clinical and molecular hepatology · 2025Article
- Efficacy of orlistat for the treatment of metabolic dysfunction-associated steatotic liver disease patients: A systematic review and meta-analysis.Hepatology forum · 2025Review
- Observational
- The prognostic impact of statin exposure in metabolic dysfunction-associated steatotic liver disease: a cohort study.Translational gastroenterology and hepatology · 2025Article
- Label-Free Optical Biopsy Reveals Biomolecular and Morphological Features of Diabetic Kidney Tissue in 2D and 3D.bioRxiv : the preprint server for biology · 2024Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.Medicina (Kaunas, Lithuania) · 2024Article
- Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Frontiers in cell and developmental biology · 2024Review
- Prognostic Value of Fibrosis-4 in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis.Clinical interventions in aging · 2024Article
- The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease.GE Portuguese journal of gastroenterology · 2023Article
- Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.Journal of clinical medicine · 2023Review
- Article
- Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?Journal of clinical medicine · 2023Review
- Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.Scientific reports · 2023Article
- Factors Associated with Liver Fibrosis in Chinese Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.International journal of general medicine · 2023Article
- Diabetic fibrosis.Biochimica et biophysica acta. Molecular basis of disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 2 countries.
Nahum Méndez-SánchezLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.ORCID 0000-0001-5257-8048
Eira Cerda-ReyesDepartment of Gastroenterology, Central Military Hospital, Mexico City, Mexico.
Fátima Higuera-de-la-TijeraDepartment of Gastroenterology, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico, Mexico.ORCID 0000-0003-3870-0478
Ana K Salas-GarcíaDepartment of Gastroenterology, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico, Mexico.
Samantha Cabrera-PalmaLiver Clinic, General Regional Hospital IMSS 1, Cuernavaca, Morelos, Mexico.
Guillermo Cabrera-ÁlvarezLiver Clinic, General Regional Hospital IMSS 1, Cuernavaca, Morelos, Mexico.
Carlos Cortez-HernándezDepartment of Gastroenterology, University Hospital "Jose Eleuterio González", Monterrey, Nuevo Leon, Mexico.
Luis A Pérez-ArredondoDepartment of Gastroenterology, University Hospital "Jose Eleuterio González", Monterrey, Nuevo Leon, Mexico.ORCID 0000-0002-6985-9599
Emma Purón-GonzálezDepartment of Internal Medicine, Christus Muguerza "Super Specialty Hospital", Monterrey, Nuevo Leon, Mexico.ORCID 0000-0003-4892-1119
Edgar Coronado-AlejandroDepartment of Internal Medicine, Christus Muguerza "Super Specialty Hospital", Monterrey, Nuevo Leon, Mexico.
Arturo PanduroDepartment of Molecular Biology in Medicine, Civil Hospital of Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico.
Heriberto Rodríguez-HernándezFaculty of Medicine and Nutrition, Juarez University of the State of Durango, Durango, Mexico.
Vania C Cruz-RamónLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.
Alejandro Valencia-RodríguezLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.ORCID 0000-0002-5201-8793
Xingshun QiDepartment of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 10016, China.ORCID 0000-0002-9448-6739
Nashla Hamdan-PérezLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.
Nancy E Aguilar-OlivosLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.
Beatriz Barranco-FragosoDepartment of Gastroenterology, National Medical Center "20 Noviembre", Mexico City, Mexico, 03229, Mexico.
Oscar Ramírez-PérezLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.
Alfonso Vera-BarajasLiver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico, 14050, Mexico.
Hospital Médica Sur · MXHospital General de México · MXHospital Universitario Dr José Eleuterio Gonzalez · MXInstituto Nacional de Salud Pública · MXUniversity of Monterrey · MXGeneral Hospital of Shenyang Military Region · CNHospital Central Militar · MXHospital Civil de Guadalajara · MXInstitute for Social Security and Services for State Workers · MXUniversidad Juárez del Estado de Durango · MX
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Non-alcoholic Fatty Liver DiseaseAdultAgedCarcinoma, HepatocellularCross-Sectional StudiesDiabetes Mellitus, Type 2DyslipidemiasFemaleHumansLiver CirrhosisLiver NeoplasmsMaleMexicoMiddle AgedRetrospective StudiesRisk Factorscirrhosisdyslipidemiametabolic syndrome.non-alcoholic fatty liver diseasetype 2 diabetes mellitus
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.